Quarterly ResultNov 10, 2026, 07:16 AM
Olema Pharmaceuticals Reports Q3 2026 Net Loss of $73.6 Million
AI Summary
Olema Pharmaceuticals, Inc. reported its third-quarter financial results for 2026, showing a significant increase in net loss to $73.6 million, up from $42.2 million in the same period of 2025. This widening loss was driven by higher operating expenses, particularly in research and development, which rose to $67.6 million from $39.9 million year-over-year. The company's balance sheet reflects a decrease in cash and marketable securities, and a reduction in total assets and stockholders' equity, while total liabilities increased.
Key Highlights
- Olema Pharmaceuticals reported a net loss of $73.6 million for Q3 2026, compared to $42.2 million in Q3 2025.
- Total operating expenses increased to $77.5 million in Q3 2026 from $45.9 million in Q3 2025.
- Research and development expenses for Q3 2026 were $67.6 million, up from $39.9 million in Q3 2025.
- Cash and cash equivalents decreased to $47.5 million as of September 30, 2026, from $48.3 million as of December 31, 2025.
- Marketable securities decreased to $366.2 million as of September 30, 2026, from $457.1 million as of December 31, 2025.
- Total assets decreased to $441.1 million as of September 30, 2026, from $533.4 million as of December 31, 2025.
- Total liabilities increased to $72.2 million as of September 30, 2026, from $54.9 million as of December 31, 2025.
- Total stockholders' equity decreased to $368.8 million as of September 30, 2026, from $478.6 million as of December 31, 2025.
Price Impact
More from OLMA